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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR BENIGN
INDICATIONS USING UMBILICAL CORD BLOOD UNITS (UCB) THAT
WERE NOT DEPLETED OF RED BLOOD CELLS
Chow, R.1, Jaing, T.-H.2, Tan, P.3, Rosenthal, J.4, Nademanee, A.4,
Karanes, C.4, Graham, M.5, Gjertson, D.6, Petz, L.1 1. StemCyte
International Cord Blood Center, Arcadia, CA; 2. Chung Gung Memo-
rial Hospital, Linko, Taiwan; 3. Mount Elizabeth Hospital, Singapore,
Singapore; 4. City of Hope National Medical Center, Duarte, CA; 5.
University of Arizona Medical Center, Tuscon, AZ; 6. UCLA Medical
Center, Los Angeles, CA.
UCB is an attractive unrelated source for HSCT of benign
indications; however, cell dosage is a critical factor for UCB
HSCT. The red cell depletion (RCD) and post-thaw wash tech-
niques that are widely used incur signiﬁcant nucleated cell loss.
Two strategies to minimize cell loss are to deplete plasma, but not
the red blood cells (PD) during processing, and forego post-thaw
wash. Eighteen thousand racially diverse PD UCB units are now
available on stem cell registries. A retrospective analysis was per-
formed on 28 patients with benign disorders who were trans-
planted with 31 PD UCB units (3 double cords) with 13 thalasse-
mias, 4 AA, 5 WAS, 2 SCID, 2 osteopetrosis, 1 sickle cell disease,
and 1 unspeciﬁed metabolic disorder. Transplant characteristics:
patient median age 4 years old (range 03–27); median weight 16 kg
(range 4.5–43); male 57%; median no. HLA ABDR matches of 4.0
(5–6/6; 7–5/6; 12–4/6; 4–3/6); median pre-freeze TNC dose 7.7
107/kg; median post-thaw TNC dose as reported by TC 7.7 
107/kg; median pre-freeze CD34 dose 3.1  105/kg; transplants
outside of U.S. 68%; non-myeloablative 6%; 25% post-thaw
washed (W), 61% infused without post-thaw wash (NW), 16%
unknown post thaw manipulation. The median time to engraft-
ment for ANC 500 (n  21), platelet 20K (n  20), and 50K (n 
18) are 17.5 days (range 11–41), 48.0 days (range 13–82), and 56.5
days (range 21–96), respectively. No major adverse event was
observed in either the W or the NW group, and the median time
to engraftment for ANC 500, platelet 20 K and 50 K for W versus
NW were 27 versus 12 days, 58 versus 44 days, and 73 versus 53
days, respectively. The unadjusted cumulative incidence (C.I.) of
ANC 500 and platelet 20 K and 50 K engraftment are 89  7%,
89  7%, and 87  8%, respectively. The incidence of reported
grade II acute GVHD was 33%, and none had grade III-IV acute
GVHD. Fifty percent developed limited chronic GVHD (7/14),
and so far only one patient was reported to have extensive chronic
GVHD. With a median follow-up of 356 days (range 93–1100
days), the Kaplan-Meier estimates of 1-year TRM, OS, and dis-
ease-free survival were 11  6%, 89  6%, and 89  6%, respec-
tively. These results demonstrate that HSCT using unrelated PD
UCB can be performed safely and effectively in patients with
benign disorders, and post-thaw washing may delay engraftment of
HSCT using PD UCB.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
INHERITED DISORDERS: EXPERIENCE IN A SINGLE-CENTER
Mattsson, J.1, Remberger, M.1, Svahn, B.-M.1, Svenberg, P.1,
Winiarski, J.2, Ringden, O.1 1. Centre for Allogeneic Stem Cell Trans-
plantation, Stockholm, Sweden; 2. Dept of Pediatrics, Stockholm, Swe-
den.
Background: Allogeneic hematopoietic stem cell transplantation
(ASCT) is a possible cure for many inherited disorders. Methods:
We report 20 years’ experience in 71 patients. The disorders
include 7 immuno-deﬁciencies, 21 hematological disorders, 13
histiocytic disorders, 9 mucopoly-saccharoidoses, 7 metachromatic
leukodystrophies (MLD), 3 adrenoleuko-dystrophies (ALD), 2 ad-
renomyeloneuropathy (AMN), 6 patients with Gaucher’s disease, 1
Sandhoff’s disease, and 2 patients with aspartylglucosaminuria.
Their median age was 4 (0–39) years. The donors were 29 HLA-
identical related, 27 matched unrelated (MUD), and 15 HLA
mismatches. Results: In recipients of HLA-identical sibling grafts,
none developed acute GVHD grades II–IV as against 22% in all
others. The overall cumulative incidence of chronic GVHD was
17%. The 5-year survival rates were 93%, 84%, and 46% in
recipients of grafts from HLA-identical siblings, MUD, and HLA-
mismatches, respectively. The overall 10-year survival rate was
69%. All of the surviving patients with immunodeﬁciencies and
hemoglobinopathies are well. Four patients with Hurler’s disease
are also well, apart from skeletal problems. Five patients with
Gaucher’s disease are between 14 and 22 years after the transplant.
Two infants with MLD deteriorated, a girl with the juvenile form
has stable disease and one woman with the adult form has im-
proved. Among 4 survivors with ALD/AMN, 3 are well and 1 has
dementia. Two patients with aspartylglucosaminuria have stable
disease. Conclusions: In patients with inborn errors of metabo-
lism, ASCT gives a high survival rate using HLA-matched donors.
Beneﬁcial effects are seen in those who are transplanted early.
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DEFIBROTIDE FOR THE TREATMENT OF SINUSOIDAL OBSTRUCTION
SYNDROME IN CHILDREN: A SINGLE INSTITUTION’S EXPERIENCE
Bulley, S.R.1, Strahm, B.1, Doyle, J.1,2, Dupuis, L.1,3 1. Division of
Haematology/Oncology, The Hospital for Sick Children, Toronto, ON,
Canada; 2. Faculty of Medicine, University of Toronto, Toronto, ON,
Canada; 3. Faculty of Pharmacy, University of Toronto, Toronto, ON,
Canada.
This retrospective report describes the experience in a single
institution with deﬁbrotide in children with sinusoidal obstruction
syndrome (SOS) following hematopoietic progenitor cell trans-
plant (HPCT). Patients who underwent HPCT between February
1999 and September 2004 and received deﬁbrotide during their
admission were identiﬁed from pharmacy records. Demographic
data and information regarding the clinical course of these patients
were abstracted from the health records. Fourteen children (mean
age: 9.3 years; range 0.4 to 18.1) received deﬁbrotide; 10 were girls.
Most patients underwent HPCT for hematologic malignancies
(8/14) and received matched unrelated donor transplants (8/14).
Conditioning regimens included cyclophosphamide (13/14),
busulphan (7/14), and TBI (5/14). SOS was diagnosed on average
on transplant day 11.4 (&minus4 to 33). Deﬁbrotide was
started on transplant day 17.5 (4 to 40) when the mean prob-
ability of developing severe SOS was 18.1% (0.1–55.3%; N  7).
The mean initial deﬁbrotide dose was 26 mg/kg/day (11 to 40
mg/kg/day); the mean maximum deﬁbrotide dose was 38.2 mg/kg/
day (11 to 81 mg/kg/day). The mean duration of deﬁbrotide
therapy was 16 days (4 to 37 days). Deﬁbrotide was discontinued
due to clinical improvement (9), death (3), drug unavailability (1),
and neurological toxicity (1). Gastrointestinal hemorrhage was
observed in 2 patients during deﬁbrotide therapy. One of these
patients continued deﬁbrotide for a further 12 days; deﬁbrotide
was stopped in the second due to its possible contribution to
neurological symptoms. Intra-cranial hemorrhage was observed in
1 patient during deﬁbrotide therapy. The survival rate to day100
was 79%. Deﬁbrotide appears to be an effective and relatively safe
treatment for children with SOS. Further research must be under-
taken to determine the pharmacokinetic disposition of deﬁbrotide
in children, its optimal dose and its adverse effect proﬁle.
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RAPID AND DURABLE ENGRAFTMENT AFTER UNRELATED CORD
BLOOD TRANSPLANTATION (CBT) FOR CHILDREN WITH TRANSFU-
SION-DEPENDENT THALASSEMIA
Jaing, T.-H.1, Rosenthal, J.2, Chow, R.3 1. Chung Gung Memorial
Hospital, Linko, Taiwan; 2. City of Hope National Medical Center,
Duarte, CA; 3. StemCyte Taiwan National Cord Blood Center, Linko,
Taiwan.
Umbilical cord blood (UCB) is an attractive unrelated source for
hematopoietic stem cell transplantation (HSCT) of thalassemia;
however, cell dosage is a critical factor for CBT. By combining
strategies that maximize cell dose, promising results may be
achieved with unrelated CBT in selected patients. Between Octo-
ber 2003 and September 2005, unrelated CBT was performed after
myeloablative therapy in 10 pediatric patients with transfusion-
dependent thalassemia at Chung Gung Memorial Hospital. All
patients were Pesaro class 1, except for 1 who was class 2. The
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median age of patients was 4.8 years old (range 2–11 years) with a
median weight of 17.5 kg (range 12–38 kg). The primary data was
audited by one of the authors at a different institution (J.R.). With
12 cord blood units for 10 patients (2 double unit CBT), there were
three 6/6, three 5/6, two 4/6, and four 3/6 high resolution HLA
A/B/DR matches. To maximize cell dose, all UCB units were
depleted of plasma but not of red blood cell (RBC), and were
thawed and infused immediately without washing. No signiﬁcant
adverse events were observed after infusion despite major ABO
incompatibility in most cases. Median pre-freeze total nucleated
cell dose was 8.7  107/kg (range 4.8–15.0  107/kg), and median
pre-freeze CD34 cell dose was 4.1  105/kg (range 2.1–8.0 
105/kg) of the recipient’s body weight. One patient died of peni-
cillin-resistant S. mitis sepsis at day 8 unrelated to the CBU. All
remaining 9 patients are alive and thalassemia free with a median
follow-up time of 378 days (range 82–713 days) as of October 8,
2005. Eight patients with neutrophil engraftment showed full do-
nor chimerism by day 21 and the remaining patient achieved
stable mixed chimerism (85.6% donor’s cells) by day 162 and is
currently at day 311 post-transplant. Autologous recovery was not
seen in any of the patients. The median times to ANC 500 en-
graftment, RBC transfusion independence, and platelet 20 K en-
graftment were 14 (range 12–4 days), 35 (range 20–50 days), and
51 (range 45–60 days) days after transplantation, respectively. All
surviving patients experienced grade I-II acute GvHD that re-
solved with treatment, with no extensive chronic GvHD. The
median day to hospital discharge was day 78 (range 46–98 days).
These results show that when cell dose is optimal, unrelated CBT
may be a promising approach for the curative therapy of thalasse-
mia major.
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BUSULFAN/MELPHALAN IS AN EFFECTIVE AND WELL TOLERATED
CONDITIONING REGIMEN FOR PEDIATRIC AML AND MDS PATIENTS
RECEIVING A MATCHED SIBLING BMT
Martin, P.L.1, Driscoll, T.A.1, Szabolcs, P.1, Parikh, S.H.1,
Prasad, V.K.1, Kurtzberg, J.1 1Duke University Medical Center,
Durham, NC.
Background: Allogeneic transplant results in the best outcomes
for pediatric patients with myeloid malignancies and matched sib-
ling donors (MRD). Improvements in supportive care, prophylaxis
of infections, and treatment of GvHD has decreased non-relapse
related morbidity and mortality. Conditioning regimens without
TBI would be expected to result in less long term toxicity, but may
not be as effective in preventing relapse. We report results of
allogeneic MRD transplantation after a busulfan (Bu) and melpha-
lan (Mel) conditioning regimen for a group of 36 pediatric patients
transplanted at a single center. Methods: From 11/93–9/05, 36
children with AML or MDS received Bu (1 mg/kg/dose  16
doses) and Mel (60 mg/m2 daily 3) followed by a 5/6 or 6/6 HLA
MRD BMT. GvHD prophylaxis was CyA and MTX. Twenty-nine
patients had AML: 19 in CR1; 3 in CR2; 7 were either induction
failures or were in relapse at the time of transplant. Seven patients
had MDS: 5 were de novo patients; 1 was a patient constitutionally
mosaic for trisomy 8, and 1 was a patient with monosomy 7
following treatment for ALL. Patients were evaluated for engraft-
ment, toxicity, relapse, and overall survival. Results: All donors
were siblings, either HLA identical (n  34) or a 5/6 match caused
by a crossover event (n  2). All patients successfully engrafted
with a median time to engraftment (ANC 	 500/uL) of 14 days.
Five patients experienced grade II acute graft-versus-host disease
(aGvHD) and 3 experienced chronic GvHD (1 limited and 2
extensive). No patient died of infection, 1 died of pulmonary
toxicity, 1 patient survived an intracranial hemorrhage with neu-
rological sequela, and 1 patient survived a diffuse pulmonary alve-
olar hemorrhage. Seven AML patients relapsed (6 in marrow and
one isolated CNS chloroma) yielding a 75% disease free survival
and an 80% overall survival. All of the marrow relapsed patients
subsequently died (4 were CR1 and 2 were in relapse at the time of
BMT). All 7 MDS patients survive disease free. With a median
follow-up of 6 years the disease free and overall survival are both
29/36 (81%). Non-relapse mortality was 1 out of 36 (3%). Con-
clusions: Bu/Mel is an effective, well tolerated conditioning reg-
imen for pediatric patients with AML or MDS. Leukemic relapse,
occurring in 25% of the AML patients, remains the main cause of
treatment failure. Additional trials are indicated to verify these
results at other pediatric transplant centers.
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UNRELATED DONOR LYMPHOCYTE INFUSIONS AS A TREATMENT OF
IMMUNODEFICIENCY IN COMPLETE DI GEORGE SYNDROME
Sedlacek, P.1, Zdrahalova, K.1, Hrusak, O.2, Mejstrikova, E.2,
Kalina, T.2, Formankova, R.1, Zizkova, H.3, Janda, A.2, Sediva, A.2,
Bartunkova, J.2, Blazek, D.4, Stary, J.1 1. Department of Pediatric
Hematology and Oncology, University Hospital Motol, Prague, Czech
Republic; 2. Department of Immunology, University Hospital Motol,
Prague, Czech Republic; 3. Institute of Hematology and Blood Transfu-
sion, Prague, Czech Republic; 4. Department of Anesthesiology,Univer-
sity Hospital Motol, Prague, Czech Republic.
Complete DiGeorge syndrome (DGS) is a rare congenital dis-
order characterized by number of developmental defects and T-
cell deﬁciency. We present an infant with multiple anomalies
(choanal and esophageal atresia, coloboma, tracheobronchomala-
cia, etc.), diagnosed at the age of 2 months with complete DGS
(absence of T cells, no response to mitogens, absent thymus),
treated with unrelated donor lymphocyte infusion (DLI). During
ﬁrst 7 months of age he required long-term ventilation, suffered
recurrent infections, and sepsis. He had no sibling and no fully
matched unrelated donor was available. At the age of 6 months the
ﬁrst dose of DLI (1  106 /kg CD3; 2 105/kg CD34) was
administered to him from an unrelated donor (mismatched for B
and Cw alleles) with no conditioning regimen and no graft versus
host disease (GVHD) prophylaxis. Ten days after DLI, he devel-
oped severe acute GVHD (skin stage 3–4) complicated with sepsis,
cardiopulmonary instability, capillary leak syndrome, and ileus. He
was treated with antithymocyte globulin (rATG), cyclosporin A
(CsA), and steroids with a complete resolution of GVHD. On day
36 after ﬁrst DL, he was given the second DLI (0.9  106/kg
CD3) with no conditioning and GVHD prophylaxis consisting
of continued CsA. EBV infection has appeared 4 weeks after
infusion (peripheral expansion of CD8 donor cells started), suc-
cessfully treated with CsA withdrawal and rituximab. Isolated cho-
lestatic liver GVHD manifested month after second DLI, pro-
gressed to stage 4, successfully treated with steroids, CsA, and
rATG. Since day 10 after ﬁrst DLI, the donor genotype due to
presence of donor T cells is documented in VNTR. Response to
mitogens appeared and is now comparable to healthy controls.
Central memory (CD27pos, CD45RAneg) stages dominate in the
peripheral blood CD4 and CD8 cells (64 to 81% and 52 to 95%,
respectively), which was higher than in control. Effector memory
cells are increased in CD4 subset, decreased in CD8. Naive CD4
T cells (CD45RApos, CD27pos) continued to be completely absent
at all time-point measured, but naive CD8 (CD45RApos, CD27pos)
were detected already at D 100 at 5% and continued raise
thereafter. The patient is now 10 months after ﬁrst DLI still on
CsA and steroids, slowly started to gain his developmental mile-
stones. We believe that infusions of small doses of DLI from an
unrelated donor represent an adequate therapy for complete Di-
George syndrome. Supported by NI 7410-3, MSM0021620812.
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STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS WITH WISKOTT
ALDRICH SYNDROME (WAS): ANALYSIS OF 19 PTS TRANSPLANTED IN
BRAZIL AND CHILE
Bonﬁm, C.1, Barriga, F.2, Wietstruck, M.A.2, Setubal, D., Ruiz, J.1,
Funke, V.1, Koliski, A.3, Bitencourt, M.1, Pasquini, R.1 1. Federal
University of Parana, Curitiba, PR, Brazil; 2. Pontiﬁcia Universidad
Catolica, Santiago, Chile; 3. Pediatric Intensive Care Unit, Curitiba,
PR, Brazil.
WAS is a rare X linked disorder characterized by eczema, throm-
bocytopenia with small platelets, and increased susceptibility to
infections autoimmune diseases and malignancies. SCT from
matched related or unrelated donors is considered the treatment of
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